Table of Content

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16

2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter’s Fiver Forces Analysis 35

3 Segmentation of Asia Pacific Market by Product Type 39
3.1 Market Overview by Product Type 39
3.2 Active Pharmaceutical Ingredients (API) 41
3.2.1 Branded Drugs 42
3.2.2 Generic Drugs 43
3.3 Finished Dosage Formulations (FDF) 44
3.3.1 Oral Solid Drugs 46
3.3.2 Injectable Drugs 47
3.3.3 Semi-solid or Liquid Drugs 48
3.3.4 Other FDFs 49

4 Segmentation of Asia Pacific Market by Service Type 50
4.1 Market Overview by Service Type 50
4.2 Preclinical Use 52
4.3 Clinical Use 53
4.3.1 Phase I 55
4.3.2 Phase II 56
4.3.3 Phase III 57
4.3.4 Phase IV 58
4.4 Commercial Use 59

5 Segmentation of Asia Pacific Market by Customer Type 60
5.1 Market Overview by Customer Type 60
5.2 Pharmaceutical Firms 62
5.3 Biotechnology Firms 63

6 Segmentation of Asia Pacific Market by Therapeutic Area 64
6.1 Market Overview by Therapeutic Area 64
6.2 Infectious Diseases 66
6.3 Oncology 67
6.4 Ophthalmology 68
6.5 Cardiovascular Disorders 69
6.6 Central Nervous System 70
6.7 Respiratory Disorders 71
6.8 Metabolic Diseases 72
6.9 Other Therapeutic Areas 73

7 Asia-Pacific Market 2021-2031 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 Japan 77
7.3 China 80
7.4 Australia 82
7.5 India 84
7.6 South Korea 86
7.7 Rest of APAC Region 88

8 Competitive Landscape 90
8.1 Overview of Key Vendors 90
8.2 New Product Launch, Partnership, Investment, and M&A 93
8.3 Company Profiles 94
Boehringer Ingelheim 94
Cambrex Corporation 96
Catalent 97
Cipla 98
Covance Inc. 99
Lonza Group Ltd. 100
Medley Pharmaceuticals 101
NatcoPharma 102
Patheon (Thermo Fisher Scientific, Inc.) 103
Piramal Pharma Solutions 104
RedHillBiopharma 105
Siegfried Holding AG 106
STA Pharmaceutical 107
Sun Pharmaceutical 108
Teva 109
RELATED REPORTS 110



List of Figures

List of Figures:

Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. Asia Pacific Small Molecule CDMO Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Small Molecule CDMO Market 24
Figure 7. Primary Restraints and Impact Factors of Asia Pacific Small Molecule CDMO Market 28
Figure 8. Investment Opportunity Analysis 32
Figure 9. Porter’s Fiver Forces Analysis of Asia Pacific Small Molecule CDMO Market 35
Figure 10. Breakdown of Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, % of Revenue 40
Figure 11. Asia Pacific Addressable Market Cap in 2022-2031 by Product Type, Value ($ mn) and Share (%) 40
Figure 12. Asia Pacific Small Molecule CDMO Market by Product Type: Active Pharmaceutical Ingredients (API), 2021-2031, $ mn 41
Figure 13. Asia Pacific Small Molecule CDMO Market by API: Branded Drugs, 2021-2031, $ mn 42
Figure 14. Asia Pacific Small Molecule CDMO Market by API: Generic Drugs, 2021-2031, $ mn 43
Figure 15. Asia Pacific Small Molecule CDMO Market by Product Type: Finished Dosage Formulations (FDF), 2021-2031, $ mn 44
Figure 16. Asia Pacific Small Molecule CDMO Market by FDF: Oral Solid Drugs, 2021-2031, $ mn 46
Figure 17. Asia Pacific Small Molecule CDMO Market by FDF: Injectable Drugs, 2021-2031, $ mn 47
Figure 18. Asia Pacific Small Molecule CDMO Market by FDF: Semi-solid or Liquid Drugs, 2021-2031, $ mn 48
Figure 19. Asia Pacific Small Molecule CDMO Market by FDF: Other FDFs, 2021-2031, $ mn 49
Figure 20. Breakdown of Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, % of Sales Revenue 51
Figure 21. Asia Pacific Addressable Market Cap in 2022-2031 by Service Type, Value ($ mn) and Share (%) 51
Figure 22. Asia Pacific Small Molecule CDMO Market by Service Type: Preclinical Use, 2021-2031, $ mn 52
Figure 23. Asia Pacific Small Molecule CDMO Market by Service Type: Clinical Use, 2021-2031, $ mn 53
Figure 24. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase I, 2021-2031, $ mn 55
Figure 25. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase II, 2021-2031, $ mn 56
Figure 26. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase III, 2021-2031, $ mn 57
Figure 27. Asia Pacific Small Molecule CDMO Market by Clinical Use: Phase IV, 2021-2031, $ mn 58
Figure 28. Asia Pacific Small Molecule CDMO Market by Service Type: Commercial Use, 2021-2031, $ mn 59
Figure 29. Breakdown of Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, % of Sales Revenue 61
Figure 30. Asia Pacific Addressable Market Cap in 2022-2031 by Customer Type, Value ($ mn) and Share (%) 61
Figure 31. Asia Pacific Small Molecule CDMO Market by Customer Type: Pharmaceutical Firms, 2021-2031, $ mn 62
Figure 32. Asia Pacific Small Molecule CDMO Market by Customer Type: Biotechnology Firms, 2021-2031, $ mn 63
Figure 33. Breakdown of Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, % of Revenue 65
Figure 34. Asia Pacific Addressable Market Cap in 2022-2031 by Therapeutic Area, Value ($ mn) and Share (%) 65
Figure 35. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Infectious Diseases, 2021-2031, $ mn 66
Figure 36. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Oncology, 2021-2031, $ mn 67
Figure 37. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Ophthalmology, 2021-2031, $ mn 68
Figure 38. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Cardiovascular Disorders, 2021-2031, $ mn 69
Figure 39. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Central Nervous System, 2021-2031, $ mn 70
Figure 40. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Respiratory Disorders, 2021-2031, $ mn 71
Figure 41. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Metabolic Diseases, 2021-2031, $ mn 72
Figure 42. Asia Pacific Small Molecule CDMO Market by Therapeutic Area: Other Therapeutic Areas, 2021-2031, $ mn 73
Figure 43. Breakdown of APAC Small Molecule CDMO Market by Country, 2021 and 2031, % of Revenue 75
Figure 44. Contribution to APAC 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 76
Figure 45. Small Molecule CDMO Market in Japan, 2021-2031, $ mn 78
Figure 46. Small Molecule CDMO Market in China, 2021-2031, $ mn 80
Figure 47. Small Molecule CDMO Market in Australia, 2021-2031, $ mn 82
Figure 48. Small Molecule CDMO Market in India, 2021-2031, $ mn 84
Figure 49. Small Molecule CDMO Market in South Korea, 2021-2031, $ mn 86
Figure 50. Small Molecule CDMO Market in Rest of APAC, 2021-2031, $ mn 88
Figure 51. Growth Stage of Asia Pacific Small Molecule CDMO Industry over the Forecast Period 90

List of Tables

List of Tables:

Table 1. Snapshot of Asia Pacific Small Molecule CDMO Market in Balanced Perspective, 2021-2031 17
Table 2. World Economic Outlook, 2021-2031 21
Table 3. Worldwide Total Number of Registered Clinical Trials 27
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Small Molecule CDMO Market 31
Table 5. Asia Pacific Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 39
Table 6. Asia Pacific Small Molecule CDMO Market: API by Type, 2021-2031, $ mn 41
Table 7. Asia Pacific Small Molecule CDMO Market: FDF by Type, 2021-2031, $ mn 45
Table 8. Asia Pacific Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 50
Table 9. Asia Pacific Small Molecule CDMO Market: Clinical Use by Type, 2021-2031, $ mn 54
Table 10. Asia Pacific Small Molecule CDMO Market by Customer Type, 2021-2031, $ mn 60
Table 11. Asia Pacific Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 64
Table 12. APAC Small Molecule CDMO Market by Country, 2021-2031, $ mn 75
Table 13. Japan Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 79
Table 14. Japan Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 79
Table 15. Japan Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 79
Table 16. China Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 81
Table 17. China Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 81
Table 18. China Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 81
Table 19. Australia Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 83
Table 20. Australia Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 83
Table 21. Australia Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 83
Table 22. India Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 85
Table 23. India Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 85
Table 24. India Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 85
Table 25. South Korea Small Molecule CDMO Market by Product Type, 2021-2031, $ mn 87
Table 26. South Korea Small Molecule CDMO Market by Service Type, 2021-2031, $ mn 87
Table 27. South Korea Small Molecule CDMO Market by Therapeutic Area, 2021-2031, $ mn 87
Table 28. Small Molecule CDMO Market in Rest of APAC by Country/Region, 2021-2031, $ mn 89
Table 29. Boehringer Ingelheim: Company Snapshot 94
Table 30. Boehringer Ingelheim: Business Segmentation 95
Table 31. Boehringer Ingelheim: Product Portfolio 95